RBC Capital has initiated coverage on Sionna Therapeutics Inc (SION) with a Sector Perform rating as of September 2, 2025. This marks the firm's first assessment of the clinical-stage biopharmaceutical company, which focuses on developing novel medicines for cystic fibrosis.
Sionna Therapeutics, headquartered in Waltham, Massachusetts, operates with a market capitalization of $1.7 billion and employs 41 full-time staff. The company is advancing a pipeline of small molecules aimed at correcting defects caused by the F508del genetic mutation in cystic fibrosis patients. Currently, Sionna is conducting Phase I trials for its two NBD1 stabilizers, SION-719 and SION-451, evaluating their safety and pharmacokinetic profiles.
The current stock price stands at $42.55. Sionna's earnings per share (EPS) for the trailing twelve months is -$2.23. The company is expected to report its next earnings on May 4, 2026, with an estimated EPS of -$0.55 and no anticipated revenue.
Analyst consensus as of November 1, 2025, reflects a Buy rating, with 5 Strong Buy, 5 Buy, 2 Hold, and no Sell ratings among a total of 12 analysts. Notably, Raymond James also initiated coverage on September 3, 2025, assigning a Strong Buy rating to Sionna Therapeutics.